Generation of a selectively cytotoxic fusion protein against p53 mutated cancers
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Generation of a selectively cytotoxic fusion protein against p53 mutated cancers ; volume:12 ; number:1 ; day:3 ; month:8 ; year:2012 ; pages:1-10 ; date:12.2012
BMC cancer ; 12, Heft 1 (3.8.2012), 1-10, 12.2012
- Urheber
-
Kousparou, Christina A.
- Beteiligte Personen und Organisationen
-
Yiacoumi, Efthymia
Deonarain, Mahendra P.
Epenetos, Agamemnon A.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-12-338
- URN
-
urn:nbn:de:1111-201603042745
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kousparou, Christina A.
- Yiacoumi, Efthymia
- Deonarain, Mahendra P.
- Epenetos, Agamemnon A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cytotoxic and targeted therapy for hereditary cancers
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers
A mutated dph3 gene causes sensitivity of Schizosaccharomyces pombe cells to cytotoxic agents
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Harmine suppresses hyper-activated Ras–MAPK pathway by selectively targeting oncogenic mutated Ras/Raf in Caenorhabditis elegans
Cytotoxic and targeted therapy for hereditary cancers
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers
A mutated dph3 gene causes sensitivity of Schizosaccharomyces pombe cells to cytotoxic agents
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Harmine suppresses hyper-activated Ras–MAPK pathway by selectively targeting oncogenic mutated Ras/Raf in Caenorhabditis elegans
Cytotoxic and targeted therapy for hereditary cancers
Cytotoxic and targeted therapy for BRCA1/2-driven cancers
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
Transcriptome Patterns of BRCA1- and BRCA2- Mutated Breast and Ovarian Cancers
Prognostic role of proliferating CD8+ cytotoxic Tcells in human cancers
A mutated dph3 gene causes sensitivity of Schizosaccharomyces pombe cells to cytotoxic agents
Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial